54 results about "Epithelial barrier" patented technology

The present invention relates to formulations and methods for the mucosal and parenteral administration of lipid particles an suspensions. The formulations of this invention are stable lipid particles useful for oral delivery of water-insoluble therapeutic agents, vaccines and diagnostics. The compositions of this invention promote the mucosal absorption of biologically active molecules across mucosal epithelial barriers. Stabilization of lipid particles is achieved by coating the hydrophobic central core with a polymer shell. The polymer shell can include bioadhesive agents, ligands, and absorption promoting agents. This invention relates to oral drug delivery systems for hydrophobic drugs, and in particular is concerned with improving the bioavailability of hydrophobic drugs from such systems. Using this system, anticancer drugs such as taxanes are orally effective.

The present invention provides lactobacillus reuteri for preventing ulcerative colitis. The strain is named as lactobacillus reuteri RAM0101 and deposited on May 27, 2019 at China General Microbiological Culture Collection Center and has a preservation number of CGMCC NO.17853. C57BL/6N mice are used as test objects, dextran sodium sulfate (DSS) is used to induce the mice to form an ulcerative colitis model and the model is also used to investigate effectiveness of the strain in preventing the ulcerative colitis. The lactobacillus reuteri can relieve weight loss, diarrhea, hematochezia and disease activity index (DAI) score of the ulcerative colitis mice induced by the DSS, protects pathological damages of colon tissues of the mice induced by the DSS, can enhance colon tissue epithelial barrier completeness and is also free of toxin and harms.

Aspects of the invention include methods for enhancing blood coagulation in a subject. In practicing methods according to certain embodiments, an amount of a non-anticoagulant sulfated polysaccharide (NASP) in combination with a gastrointestinal epithelial barrier permeation enhancer is orally administered to a subject in a manner sufficient to enhance blood coagulation in the subject. Compositions and kits for practicing methods of the invention are also described.

Described herein are novel compositions, targeted therapeutic methods, and assays for neutralizing and/or inhibiting the activity of “oxazole-containing (OxC) compounds,” to prevent or delay the onset of epithelial barrier dysfunction and chronic inflammation associated with various disorders, such as colitis.

This invention relates to a transdermal drug formulation that includes a pharmaceutically suitable carrier; an effective amount of a therapeutic agent; and a histamine type 4 receptor (“H4R”) agonist, as well as a transdermal vaccine formulation that includes a pharmaceutically suitable carrier; an effective amount of an antigen or antigen-encoding nucleic acid molecule present in the carrier, and optionally one or more adjuvants; and an H4R agonist. The present invention also relates to transdermal delivery device including such formulations and methods of administering such formulations. The present invention also relates to methods of enhancing epithelial barrier formation in a patient involving administering to the patient at a site of epithelial disruption an amount of a formulation that comprises an H4R antagonist. The present invention also relates to a method of inhibiting pathogen infection or local spread of infection in the epithelia using an H4R antagonist, an H1R antagonist, or a combination thereof.

Peptide ligands for transporting therapeutic agents across the intestinal epithelial barrier that ordinarily are inadequately absorbed and must be delivered by alternative means, which contain an isolated amino acid sequence wherein at least one pair of amino acids are of an opposite charge and the pair members are separated by a spacer of 1-12 amino acid residues including at least one hydrophobic amino acid, and wherein the length of the amino acid sequence is greater than 5 and less than 20 amino acids. Pharmaceutical compositions for gastro-intestinal delivery and methods for the gastrointestinal delivery of poorly absorbed therapeutic agents are also disclosed.

The present invention concerns strains of Lactococcus lactis capable of inhibiting the growth of a pathogenic microorganism and/or improving the intestinal epithelial barrier integrity. These strains are suitable for use in the treatment or prevention of a digestive disorder.

The invention provides a trace element-loaded yeast micro-nano robot sugar pill, which is characterized by comprising an external polysaccharide coat and at least one internal yeast micro-nano robot, the yeast micro-nano biological robot is composed of yeast cells, biological enzyme and trace elements, wherein the yeast cells are half-covered with the biological enzyme, and the trace elements are loaded in the yeast cells. The polysaccharide coat of the yeast micro-nano robot sugar pill can be degraded in the intestinal tract to release a yeast micro-nano robot carrying trace elements, and the yeast micro-nano robot can utilize glucose in the intestinal tract as power to autonomously move, so that the yeast micro-nano robot can penetrate through mucus barriers, epithelial barriers and other barriers to reach the intestinal wall, and absorption of the organism to the trace elements is efficiently promoted.

Methods and materials relating to cultured choroid plexus organoids comprising: (a) an epithelium comprising a tight epithelial barrier; and/or (b) one or more cysts surrounded by an epithelium, plus other authentic features and markers.

The invention belongs to the field of medicine and relates to an application of lysophosphatidylethanolamine 18: 1 in preparing a drug for relieving and treating inflammatory bowel diseases. The invention discloses that lysophosphatidylethanolamine 18: 1 alleviates or treats enteritis and inflammatory bowel diseases by increasing the stability of intestinal epithelial barrier. The lysophosphatidylethanolamine 18: 1 is an effective drug for the treatment of inflammatory bowel diseases.

The present invention provides compositions and methods for treating hyperglycemia, insulin resistance, and associated organ damage, including in some embodiments diabetes mellitus (type 1 or 2), metabolic syndrome, obesity, fatty liver diseases, or kidney disease. In various embodiments, the invention involves administering a regimen of larazotide (or a derivative of larazotide) to a subject. In various embodiments, the regimen reduces dysfunction of the gastrointestinal epithelial barrier, thereby improving glycemic control. In various embodiments, the regimen of larazotide improves the effectiveness of conventional pharmaceutical interventions for hyperglycemia or diabetes mellitus.

The anatomic and functional arrangement of the gastrointestinal tract suggests an important function of this organ is its ability to regulate the trafficking of metabolites as well as control the equilibrium between tolerance and immunity through gut-associated lymphoid tissue, the neuroendocrine network, and the intestinal epithelial barrier. Combining nucleated cells from various tissues and introducing them directly into the small intestine will have a positive effect on diabetes.

The invention discloses an application of puerarin for preventing, treating and/or relieving irritable bowel syndrome. The puerarin can restore retarded cell cycles and promote the proliferation of intestinal epithelial cells by up-regulating the level of phosphorylated extracellular regulatory protein kinase (p-ERK). The puerarin can participate in the repair of the intestinal epithelial barrier by up-regulating expression of tight junction protein (occulting), and inhibit the hyperfunction of the hypothalamic-pituitary-adrenal axis (HPA axis) by down-regulating expression of hypothalamic corticotropin release factor (CRF1) receptor protein, and improve the gastrointestinal motility and visceral hypersensitivity. Tests prove that puerarin has a remarkable curative effect on the irritable bowel syndrome, takes effect quickly and has small side effects. The puerarin is an efficient, safe, stable medicine with extensive sources for treating the irritable bowel syndrome. The puerarin of the invention provides a new medicine source for preventing and treating the irritable bowel syndrome and complications thereof.

The invention discloses pediococcus pentosaceus antagonistic to escherichia coli O157: H7 and application of the pediococcus pentosaceus antagonistic to escherichia coli O157: H7. The pediococcus pentosaceus is pediococcus pentosaceus IM96 and is preserved in the Guangdong Microbial Culture Collection Center on May 17, 2021, with an accession number being GDMCC NO: 61654. Viable bacteria and fermentation supernatant of the pediococcus pentosaceus have good antibacterial activity, and especially have strong antagonistic activity on escherichia coli O157: H7 in vitro and in vivo. In addition, the pediococcus pentosaceus has good tolerance to gastrointestinal fluid, is high in safety, and can relieve and improve intestinal pathological injury, intestinal inflammation and intestinal epithelial barrier injury caused by escherichia coli O157: H7 in vivo. The pediococcus pentosaceus can be used for preparing medicines, food or food additives, animal feeds and microbial preparations with antibacterial activity in the future, and has good application prospects.